PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
about
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancerPredictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of OptionsCurrent targeted therapies in the treatment of advanced colorectal cancer: a reviewPharmacologic resistance in colorectal cancer: a reviewTreatment Individualization in Colorectal CancerPrecision medicine in colorectal cancer: the molecular profile alters treatment strategiesPIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysisPrimary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategiesMeta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancerBiomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis.The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.Toward the molecular dissection of peritoneal pseudomyxoma.Pharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyondConcordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastasesThe Role of PTEN in Tumor AngiogenesisPrognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysisThe role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target.Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation.Systems approach for the selection of micro-RNAs as therapeutic biomarkers of anti-EGFR monoclonal antibody treatment in colorectal cancer.DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset.Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patientsEGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancerCurrent approaches for predicting a lack of response to anti-EGFR therapy in KRAS wild-type patientsScreening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study.New trends in epidermal growth factor receptor-directed monoclonal antibodies.Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours.KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients.The prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: a meta-analysis.FISH analysis of PTEN in endometrial carcinoma. Comparison with SNP arrays and MLPA.Differential expression of IL-17, 22 and 23 in the progression of colorectal cancer in patients with K-ras mutation: Ras signal inhibition and crosstalk with GM-CSF and IFN-γNovel points of attack for targeted cancer therapy.Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients.Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancerCan we accurately report PTEN status in advanced colorectal cancer?Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type statusKRAS, NRAS, BRAF mutation comparison of endoscopic and surgically removed primary CRC paired samples: is endoscopy biopsy material adequate for molecular evaluation?KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer.CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomasNovel drugs targeting the epidermal growth factor receptor and its downstream pathways in the treatment of colorectal cancer: a systematic review
P2860
Q21142734-398534C9-E30E-461C-B63F-4AAECED1CBACQ26738655-699593A4-39C6-4DF9-AD5B-726A70ABFF0DQ26740067-68720FFA-C4CF-4893-923E-498B64A98872Q26769850-72642181-2F40-42ED-B656-DFCA96A41D4AQ26776215-A47567B3-2C6E-4D38-B987-E40BC5EC4F05Q26795558-F9481B41-5A38-44D2-849D-5B82A7505B20Q26992267-9F8B66E1-9FD8-430E-9DB8-0EE7598319FAQ27015224-0766D25B-3729-434C-B83D-FBB473A63A44Q27027648-8B4F58B3-65A6-413A-9393-298BAD43B783Q27852062-D7AB045A-B9D3-409D-904F-075DF8895D4BQ27852105-8A47E7AE-2934-4D5E-8F45-CC590886FF59Q27852988-E15678D6-055B-469A-98CF-348D556B72D3Q27853397-313F5A6D-36F5-4969-B600-70E5FDF9DDF9Q28080730-2A5929B3-19DA-45F9-A2F6-53D5CB37950CQ28088489-C9061940-1C14-464B-B3F9-7BF50701640CQ28391620-6A4D80A8-5367-4493-A408-BB54B046CC3EQ30248900-79AE1E67-8666-4EFD-91E8-90F8FEFA7F90Q33274011-223DEF2E-658C-45E4-9DA9-82FD2F3A28C8Q33412380-DA6D5FE5-8858-418F-81E2-72E1C2560949Q33556004-16009129-A3BD-4D73-A233-1C9BA916BD62Q33754380-88B2257B-1F4F-4994-8A7F-5878FF577F70Q33809458-4DD54632-425A-474E-B04F-21834799BEA0Q33856378-896EDAED-B182-4C87-B42D-CE44885AA3E4Q33861210-BFF48348-9617-4BB9-BF39-2079B7936E4EQ34497010-44021744-162A-409B-9F56-EA449D445BC5Q34621577-8564221F-F8CA-463E-9A6E-E6674A3A81E2Q34634536-6F64C877-8283-4CD6-8D39-0EFA4DF92BEAQ34727184-EC9C2612-07FE-4C77-BCF8-82C68FE3A61DQ34776118-63A6A67D-3E14-43AC-82C8-54EBB0F3A38AQ34805622-447B6E8C-4ABB-44AD-93B2-FAF2C71CD46EQ34989005-A2BCCB59-E41C-4BDC-B85A-50497E708047Q35023279-395006ED-BFD3-4183-8591-628C924EB55BQ35034638-B646B5B4-72D5-4F63-9435-B68EE803768CQ35076220-3410C4FE-674D-4805-905F-F9855ED6CC1AQ35101357-6CEE6E40-1A1F-458D-AE02-67CC304AFC4FQ35137474-783E6DAB-C5E2-47B0-B763-56E22936D11BQ35760814-850942B1-FDD3-403F-9182-F863EDFAAEB6Q36089917-1226D8ED-319B-4E8F-8401-3E1CB66F730CQ36211422-D63117B4-0718-4BFD-833F-0BCFD2EDB4CAQ36337063-E0380F89-F5A7-4B05-B8E3-E5A56683DBB3
P2860
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
PI3KCA/PTEN deregulation contr ...... tic colorectal cancer patients
@en
PI3KCA/PTEN deregulation contr ...... tic colorectal cancer patients
@nl
type
label
PI3KCA/PTEN deregulation contr ...... tic colorectal cancer patients
@en
PI3KCA/PTEN deregulation contr ...... tic colorectal cancer patients
@nl
prefLabel
PI3KCA/PTEN deregulation contr ...... tic colorectal cancer patients
@en
PI3KCA/PTEN deregulation contr ...... tic colorectal cancer patients
@nl
P2093
P2860
P50
P921
P356
P1433
P1476
PI3KCA/PTEN deregulation contr ...... tic colorectal cancer patients
@en
P2093
A Gevorgyan
M Frattini
M Orsenigo
S Andreola
P2860
P356
10.1093/ANNONC/MDN541
P577
2008-07-22T00:00:00Z